

Brenda J Weigel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7698234/publications.pdf>

Version: 2024-02-01

18
papers

449
citations

840776

11
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

745
citing authors

#	ARTICLE	IF	CITATIONS
1	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
2	Successful management of an arteriovenous malformation with trametinib in a patient with capillary malformation arteriovenous malformation syndrome and cardiac compromise. <i>Pediatric Dermatology</i> , 2022, 39, 316-319.	0.9	19
3	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	2.8	28
4	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. <i>European Journal of Cancer</i> , 2022, 173, 71-90.	2.8	9
5	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. <i>Cancer Medicine</i> , 2021, 10, 843-856.	2.8	3
6	Racial and Ethnic Differences in Sarcoma Incidence Are Independent of Census-Tract Socioeconomic Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2141-2148.	2.5	9
7	Associations of Socioeconomic Status, Public vs Private Insurance, and Race/Ethnicity With Metastatic Sarcoma at Diagnosis. <i>JAMA Network Open</i> , 2020, 3, e2011087.	5.9	19
8	Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF03084014) in desmoid tumor: Report of four pediatric/young adult cases. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28636.	1.5	15
9	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52
10	Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28288.	1.5	13
11	Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps. <i>Sarcoma</i> , 2020, 2020, 1-7.	1.3	13
12	The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma. <i>Cancer</i> , 2019, 125, 290-297.	4.1	60
13	Identification of aggressive Gardner syndrome phenotype associated with a de novo <i>APC</i> variant, c.4666dup. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003640.	1.2	8
14	Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 38.	3.0	2
15	Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. <i>American Journal of Hematology</i> , 2012, 87, 953-956.	4.1	50
16	CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2003, 9, 3105-14.	7.0	109
17	Retinoblastoma and Hirschsprung disease in a patient with interstitial deletion of chromosome 13. , 1998, 77, 285-288.		16
18	Congenital Infantile Fibrosarcoma Involving Pelvic Wall and Thigh Soft Tissues and Placenta, Presenting with Coagulopathy. <i>Pediatric and Developmental Pathology</i> , 0, , 109352662211140.	1.0	0